← Leaderboards
Ralph R Weichselbaum
University Of Alabama At Birmingham
$16,065,057
Attributed
$20,331,734
Total exposure
19
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,465,328 · 20
By mechanism
R01$12,168,264 · 9
U54$6,133,594 · 1
U01$3,036,595 · 1
R21$1,960,080 · 5
P01$1,646,615 · 2
P50$1,384,706 · 1
Top collaborators
- Wenbin Lin12 shared
- Joseph O Deasy5 shared
- Silvia C Formenti5 shared
- Stephen J. Kron2 shared
- Mark Mimee2 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Thomas M Ryan$5,321,710
- Yogesh K Vohra$7,770,405
- Eleonore Beurel$7,525,473
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorRadiation TherapyRadiationMalignant NeoplasmsMediatingResponseCellsImmuneResistanceToxic EffectDoseClinical TrialsGenesNeoplastic CellImmune SystemAntitumor EffectImmunotherapyDesignCancer PatientCancer TherapyTumor MicroenvironmentMolecularChemotherapyIrradiated Tumor
Grant awards (64)
Dynamics of Immune Response in Irradiated Rectal Cancer$1,275,371
U54 · FY2025 · CA
Genetically-engineered Bacteria Overcome Therapy Resistance$594,699
R01 · FY2025 · CA · contact PI
Tumor-Targeted Multimodality Nanoscale Coordination Polymers for Chemo-Immunotherapy of Metastatic Colorectal Cancer$466,819
R01 · FY2025 · CA · contact PI
Nanoscale Coordination Polymers of Cyclic-di-nucleotides and Peptide Antigens for Effective Therapy of Metastatic Colorectal Cancer$443,412
R01 · FY2025 · CA · contact PI
Elucidating the Roles of RNA m6A readers Y1 and Y2 in radiation-induced immunity and immunotherapy$405,225
R01 · FY2025 · CA · contact PI
Dynamics of Immune Response in Irradiated Rectal Cancer$1,423,932
U54 · FY2024 · CA
Genetically-engineered Bacteria Overcome Therapy Resistance$581,087
R01 · FY2024 · CA · contact PI
Nanoscale Metal-Organic Frameworks Enable Radiotherapy-Radiodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Generate Tumor Vaccines and Potentiate Immunotherapy of Head and Neck Cancers$479,142
R01 · FY2024 · CA
Nanoscale Coordination Polymers of Cyclic-di-nucleotides and Peptide Antigens for Effective Therapy of Metastatic Colorectal Cancer$423,829
R01 · FY2024 · CA · contact PI
Elucidating the Roles of RNA m6A readers Y1 and Y2 in radiation-induced immunity and immunotherapy$392,077
R01 · FY2024 · CA · contact PI
A Digital Twin for rectal cancer to guide adaptive radiotherapy$246,001
U54 · FY2024 · CA
Dynamics of Immune Response in Irradiated Rectal Cancer$1,477,107
U54 · FY2023 · CA
Nanoscale Metal-Organic Frameworks Enable Radiotherapy-Radiodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Generate Tumor Vaccines and Potentiate Immunotherapy of Head and Neck Cancers$494,273
R01 · FY2023 · CA
Nanoscale Coordination Polymers of Cyclic-di-nucleotides and Peptide Antigens for Effective Therapy of Metastatic Colorectal Cancer$446,134
R01 · FY2023 · CA · contact PI
Elucidating the Roles of RNA m6A readers Y1 and Y2 in radiation-induced immunity and immunotherapy$404,457
R01 · FY2023 · CA · contact PI
In vivo CRISPR-screening of novel cancer cell-intrinsic targets that sensitize to local ionizing radiation, and possible combination with systemic checkpoint blockade.$184,822
R21 · FY2023 · CA · contact PI
Dynamics of Immune Response in Irradiated Rectal Cancer$1,711,183
U54 · FY2022 · CA
Nanoscale Metal-Organic Frameworks Enable Radiotherapy-Radiodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Generate Tumor Vaccines and Potentiate Immunotherapy of Head and Neck Cancers$494,273
R01 · FY2022 · CA
Elucidating the Roles of RNA m6A readers Y1 and Y2 in radiation-induced immunity and immunotherapy$404,457
R01 · FY2022 · CA · contact PI
In vivo CRISPR-screening of novel cancer cell-intrinsic targets that sensitize to local ionizing radiation, and possible combination with systemic checkpoint blockade.$240,831
R21 · FY2022 · CA · contact PI
Nanoscale Metal-Organic Frameworks Enable Radiotherapy-Radiodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Generate Tumor Vaccines and Potentiate Immunotherapy of Head and Neck Cancers$504,359
R01 · FY2021 · CA
Elucidating the Roles of RNA m6A readers Y1 and Y2 in radiation-induced immunity and immunotherapy$412,712
R01 · FY2021 · CA · contact PI
Nanoscale Metal-Organic Frameworks Enable Radiotherapy-Radiodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Generate Tumor Vaccines and Potentiate Immunotherapy of Head and Neck Cancers$517,263
R01 · FY2020 · CA
Microbiota and the anti-tumor action of anti-CD47 immunomodulation.$211,410
R21 · FY2020 · CA · contact PI
Therapeutic use of T cells engineered to produce radiation-inducible cytokines$211,410
R21 · FY2020 · CA · contact PI
Nanoscale Metal-organic Frameworks for Light Triggered and X-ray Induced Photodynamic Therapy of Head and Neck Cancers$558,499
U01 · FY2019 · CA
Image-guided radiation-induced permeability (IGRIP) for IGDD$472,098
R01 · FY2019 · CA
(PQ10) Understanding How Commensal Microbiota Affect the Anti-tumor Action of Radiotherapy$205,067
R21 · FY2019 · CA · contact PI
Microbiota and the anti-tumor action of anti-CD47 immunomodulation.$176,175
R21 · FY2019 · CA · contact PI
Therapeutic use of T cells engineered to produce radiation-inducible cytokines$176,175
R21 · FY2019 · CA · contact PI
Nanoscale Metal-organic Frameworks for Light Triggered and X-ray Induced Photodynamic Therapy of Head and Neck Cancers$575,774
U01 · FY2018 · CA
Image-guided radiation-induced permeability (IGRIP) for IGDD$489,602
R01 · FY2018 · CA
(PQ10) Understanding How Commensal Microbiota Affect the Anti-tumor Action of Radiotherapy$176,175
R21 · FY2018 · CA · contact PI
Nanoscale Metal-organic Frameworks for Light Triggered and X-ray Induced Photodynamic Therapy of Head and Neck Cancers$750,774
U01 · FY2017 · CA
Enhancing the abscopal effect in cancer treatment by immune modulation$171,825
R21 · FY2017 · CA · contact PI
Nanoscale Metal-organic Frameworks for Light Triggered and X-ray Induced Photodynamic Therapy of Head and Neck Cancers$575,774
U01 · FY2016 · CA
Enhancing the abscopal effect in cancer treatment by immune modulation$206,190
R21 · FY2016 · CA · contact PI
Nanoscale Metal-organic Frameworks for Light Triggered and X-ray Induced Photodynamic Therapy of Head and Neck Cancers$575,774
U01 · FY2015 · CA
P-3: Radiation Inducible TNF-a Therapy for Prostate Cancer$237,163
P50 · FY2013 · CA · contact PI
Radiation Enhancement of HSV Anti-Tumor Effects$232,718
P01 · FY2013 · CA · contact PI
Radiation Enhancement of HSV Anti-Tumor Effects$243,884
P01 · FY2012 · CA · contact PI
P-3: Radiation Inducible TNF-a Therapy for Prostate Cancer$220,500
P50 · FY2012 · CA · contact PI
P-3: Radiation Inducible TNF-a Therapy for Prostate Cancer$301,261
P50 · FY2011 · CA · contact PI
Radiation Enhancement of HSV Anti-Tumor Effects$243,810
P01 · FY2011 · CA · contact PI
P-3: Radiation Inducible TNF-a Therapy for Prostate Cancer$300,237
P50 · FY2010 · CA · contact PI
Radiation Enhancement of HSV Anti-Tumor Effects$252,444
P01 · FY2010 · CA · contact PI
Radiation Inducible TNF-a Therapy for Prostate Cancer$325,545
P50 · FY2009 · CA · contact PI
Mechanisms of Resistance to Radio Inducible Gene Therapy$287,454
R01 · FY2009 · CA · contact PI
DNA Damage Targeted Gene Therapy in Head & Neck Cancer$263,254
R01 · FY2009 · CA · contact PI
Radiation Enhancement of HSV Anti-Tumor Effects$251,722
P01 · FY2009 · CA · contact PI
Mechanisms of Resistance to Radio Inducible Gene Therapy$287,454
R01 · FY2008 · CA · contact PI
DNA Damage Targeted Gene Therapy in Head & Neck Cancer$263,390
R01 · FY2008 · CA · contact PI
Mechanisms of Resistance to Radio Inducible Gene Therapy$287,454
R01 · FY2007 · CA · contact PI
DNA Damage Targeted Gene Therapy in Head & Neck Cancer$264,963
R01 · FY2007 · CA · contact PI
Mechanisms of Resistance to Radio Inducible Gene Therapy$296,039
R01 · FY2006 · CA · contact PI
DNA Damage Targeted Gene Therapy in Head & Neck Cancer$275,965
R01 · FY2006 · CA · contact PI
Gene Therapy for Extension of Vein Graft Patency$309,888
R01 · FY2005 · HL
Mechanisms of Resistance to Radio Inducible Gene Therapy$301,517
R01 · FY2005 · CA
DNA Damage Targeted Gene Therapy in Head &Neck Cancer$282,607
R01 · FY2005 · CA
Gene Therapy for Extension of Vein Graft Patency$310,758
R01 · FY2004 · HL
Gene Therapy for Extension of Vein Graft Patency$311,603
R01 · FY2003 · HL
DESIGN OF GENETICALLY ENGINEERED HSV FOR CANCER THERAPY$206,819
P01 · FY2001 · CA
DESIGN OF GENETICALLY ENGINEERED HSV FOR CANCER THERAPY$215,218
P01 · FY2000 · CA
TRAINING PROGRAM IN ENVIRONMENTAL BIOLOGY (NRSA)$135,474
T32 · FY2000 · CA